Alpha 2.0
Login Register
» Articles » PMID: 33310737

C Dosimetry Scans Should Be Abandoned

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2020 Dec 14
PMID 33310737
Citations 19
Authors
Paolo Zanotti-Fregonara
Adriaan A Lammertsma
Robert B Innis
Affiliations
Soon will be listed here.
Citing Articles

[F]SF51, a novel F-labeled PET radioligand for translocator protein 18kDa (TSPO) in brain, works well in monkeys but fails in humans.

Yan X, Simeon F, Liow J, Morse C, Jana S, Montero Santamaria J J Cereb Blood Flow Metab. 2024; 45(2):365-372.

PMID: 39654356 PMC: 11629344. DOI: 10.1177/0271678X241304924.

First-in-human evaluation of 6-bromo-7-[C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues.

Mairinger S, Jackwerth M, Chalampalakis Z, Rausch I, Weber M, Wolfl-Duchek M Eur J Nucl Med Mol Imaging. 2024; 51(13):3900-3911.

PMID: 39060376 PMC: 11527933. DOI: 10.1007/s00259-024-06851-2.

Process validation and preclinical development of a new PET cerebral blood flow tracer [C]MMP for initial clinical trials.

Toyohara J, Tago T, Sakata M EJNMMI Radiopharm Chem. 2024; 9(1):53.

PMID: 39042331 PMC: 11266321. DOI: 10.1186/s41181-024-00285-9.

Advancing 6-bromo-7-[C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates.

Mairinger S, Jackwerth M, Soukup O, Blaickner M, Decristoforo C, Nics L EJNMMI Radiopharm Chem. 2024; 9(1):34.

PMID: 38683266 PMC: 11058743. DOI: 10.1186/s41181-024-00265-z.

Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases.

Tago T, Sakata M, Kanazawa M, Yamamoto S, Ishii K, Toyohara J Eur J Nucl Med Mol Imaging. 2024; 51(8):2193-2203.

PMID: 38441662 DOI: 10.1007/s00259-024-06666-1.

References
1.
Parsey R, Belanger M, Sullivan G, Simpson N, Stabin M, Van Heertum R . Biodistribution and radiation dosimetry of 11C-WAY100,635 in humans. J Nucl Med. 2005; 46(4):614-9. View
2.
Laymon C, Narendran R, Mason N, Carney J, Lopresti B, Mathis C . Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ). Mol Imaging Biol. 2011; 14(1):115-22. DOI: 10.1007/s11307-011-0478-2. View
3.
Zanotti-Fregonara P, Lammertsma A, Innis R . Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013; 40(11):1781-3. PMC: 3844925. DOI: 10.1007/s00259-013-2512-x. View
4.
Doss M, Kolb H, Walsh J, Mocharla V, Fan H, Chaudhary A . Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers. J Nucl Med. 2013; 54(12):2087-92. PMC: 7607624. DOI: 10.2967/jnumed.113.119800. View
5.
Pandit-Taskar N, ODonoghue J, Ruan S, Lyashchenko S, Carrasquillo J, Heller G . First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. J Nucl Med. 2016; 57(12):1858-1864. PMC: 5450345. DOI: 10.2967/jnumed.116.176206. View